Asset Details
Do you wish to reserve the book?
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
Do you wish to request the book?
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Strategies of Radioiodine Ablation in Patients with Low-Risk Thyroid Cancer
2012
Overview
This trial compared two thyrotropin-stimulation methods and two 131I doses for postoperative ablation in patients with low-risk thyroid cancer. Rates of ablation were similar in all treatment groups. Doses lower than those currently recommended may be adequate for this condition.
Radioiodine (
131
i) is administered to patients with thyroid cancer after total thyroidectomy for three reasons
1
–
3
: first, to eradicate normal-thyroid remnants (ablation) in order to achieve an undetectable serum thyroglobulin level; second, to irradiate any neoplastic focus in order to decrease the risk of recurrence; and third, to perform
131
I total-body scanning for persistent carcinoma.
Successful ablation is defined by the combination of undetectable serum thyroglobulin levels after thyrotropin stimulation and normal results on neck ultrasonography 6 to 12 months after
131
I administration.
2
,
3
When these criteria are met, approximately 1% of patients have a recurrence.
4
–
6
In . . .
Publisher
Massachusetts Medical Society
Subject
/ Adenocarcinoma, Follicular - drug therapy
/ Adenocarcinoma, Follicular - radiotherapy
/ Adenocarcinoma, Follicular - surgery
/ Adult
/ Biological and medical sciences
/ Cancer
/ Carcinoma, Papillary - drug therapy
/ Carcinoma, Papillary - radiotherapy
/ Carcinoma, Papillary - surgery
/ Female
/ Humans
/ Iodine
/ Iodine Radioisotopes - adverse effects
/ Iodine Radioisotopes - therapeutic use
/ Male
/ Neck
/ Non tumoral diseases. Target tissue resistance. Benign neoplasms
/ Thyroid Hormones - therapeutic use
/ Thyroid Neoplasms - drug therapy
/ Thyroid Neoplasms - radiotherapy
/ Thyroid. Thyroid axis (diseases)
/ Thyrotropin - adverse effects
